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general hospital (PB 6M€ ). We chose 24 active ingredients (95 different antibiotics) 
that represent about 1/3 of total hospital antibiotics and 80% of the total anti-
biotics’ budget. We studied their consumption for the years 2011 and 2012 and 
calculated the costs based on the official drug pricelist and their price after the 
negotiation. Results: From 2011 to 2012 the discounts gained from each hospital 
were increased. Price negotiation does not apply in prototype drugs that their com-
panies are only obliged to offer a 5% rebate. Unfortunately, these medications are 
more expensive, represent 36% of the studied antibiotics’ cost and their consump-
tion was increased by 20%. But, the discounts for all the studied off-patent drugs 
and their generics were from 12.8% till 89.9%. Thus, the total cost saving for them 
was 33.2% at PAGNI, 26.0% at Evaggelismos and 43.1% at Tzaneio. The total benefit 
for the pharmaceutical expenditure was 3% for both PAGNI and Evaggelismos, and 
6% for Tzaneio. ConClusions: Price negotiation is an effective mean of decreas-
ing the cost of off-patent and generic drugs but newer and expensive drugs get 
doctors’ preference, undermining the Pharmacy’s cost-saving effort.
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objeCtives: To estimate the costs and benefits of patient pathways incorporating 
a point of care nucleic acid amplification test (POC NAAT) for chlamydia and gonor-
rhoea in genito-urinary medicine (GUM) clinics in the UK compared with standard 
off-site laboratory testing. Methods: We simulated 1.2 million men and women 
GUM clinic attendees based on GUMCAD reports from the UK (2011). A Markov 
model with Monte Carlo simulation in Microsoft Excel was developed to compare 
existing standard pathways of testing and treatment for chlamydia and gonorrhoea 
with a POC NAAT. We conducted sensitivity analyses to evaluate the robustness of 
the model findings. The primary outcome was the incremental cost-effectiveness 
ratio (ICER = £/QALY). Secondary outcomes included the number of inappropriate 
treatments, complications and transmissions averted and change in time from test 
to treatment. Results: The total cost of using the POCT in our cohort was £103.3 
million compared with £113.9 million for standard care. The ICER was -£4,182/QALY, 
making the new pathways cost saving. Nearly 100,000 inappropriate treatments 
might be avoided by using a POC NAAT. Patients receive diagnosis and treatment on 
the same day as testing, which may also prevent 162 cases of pelvic inflammatory 
disease and 17,561 transmissions. ConClusions: Replacing standard laboratory 
tests for chlamydia and gonorrhoea with a POCT could be cost saving and patients 
would benefit from more accurate diagnosis and less unnecessary treatment. 
Overtreatment currently accounts for about a tenth of the reported treatments for 
chlamydia and gonorrhoea and POC NAATs would effectively eliminate the need 
for presumptive treatment.
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objeCtives: Rotavirus (RV) causes highly contagious gastroenteritis especially in 
children under five years of age. Since 2006, two RV-vaccines are available in Europe 
(Rotarix® and RotaTeq®). We evaluated the cost-effectiveness of these vaccines for 
the German health care setting, inter alia to support an informed decision-making 
concerning a potential vaccination-recommendation. Methods: A Markov Model 
was developed to evaluate the cost-effectiveness from the statutory health insur-
ance (SHI) (direct costs) and from the societal perspective (SHI plus indirect costs). 
Health outcomes considered were RV-cases prevented, RV-associated hospitalizations 
avoided, and quality-adjusted life-years (QALY) gained. RV-incidences were derived 
from the national mandatory disease reporting system. RV-vaccine efficacy was cal-
culated as pooled estimates based on data from randomized controlled trials. Costs 
(reference year 2010) were derived from official price catalogues. An annual discount 
rate of 3% for effects and costs was applied. The first five life-years were considered as 
model’s time horizon. Results: The base-case analysis (SHI-perspective) resulted in 
an incremental cost-effectiveness and cost-utility ratio (ICER) for Rotarix® of € 184 per 
RV-case prevented, € 2,457 per RV-associated hospitalization avoided, and € 116,973 
per QALY gained. For RotaTeq®, the results were slightly higher (€ 234, € 2,622, and € 
142,732, respectively). In sensitivity analyses parameter variation showed effects on 
the ICERs without changing the overall trend. A threshold analysis suggests that cost-
saving scenarios are possible with vaccine prices reduced by ~62-66%. When applying 
base-case scenario results to the 2012 birth-cohort with 80% vaccination coverage, an 
estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be 
prevented in this birth-cohort over 5 years for an incremental cost of 44.5-48.2 million 
Euros. ConClusions: Routine RV-vaccination is expected to prevent a consider-
able number of RV-cases and RV-associated hospitalizations in Germany. Though, the 
amount of QALYs gained is low. With current vaccine prices, RV-vaccination is not a 
cost-saving preventive measure.
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boceprevir. Total costs of AE and discontinuation were $10,443 and $3,736 for telaprevir 
and boceprevir treated groups, respectively. The results were not sensitive to variation 
in treatment practices and costs. ConClusions: The costs of treatment of cirrhotic 
non-responders during the first 16 weeks were estimated to increase by 18% over triple 
therapy costs due to AEs. These data indicate that the total cost per cure may be sub-
stantially higher than the drug costs and underscore the importance of evaluating total 
cost of HCV treatment when selecting new agents.
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objeCtives: Current guidelines for the treatment of acute bacterial skin and skin 
structure infections (ABSSSI) recommend several treatment pathways based on the 
infection types and severity. The objective of this study is to establish the health 
care resource utilization (HRU) and costs associated with the most common patient 
treatment pathways in US. Methods: The medical and pharmacy administrative 
claims of adult ABSSSI patients with continuous commercial or Medicare Advantage 
enrollment with Part D prescription drug coverage between 01 January 2009 and 
31 December 2011 were extracted from a large national health plan affiliated with 
OptumInsight. The four most common treatment pathways were identified based on 
the evidences of antibiotics over the entire ABSSSI treatment course. All four path-
ways start with vancomycin IV use during a hospital stay. At discharge, patients fol-
lowed one of four pathways: 1) continue IV vancomycin as an Outpatient Parenteral 
Antibiotic Therapy (OPAT); 2) switch to oral linezolid; 3) switch to daptomycin; or 4) 
switch to any oral antibiotic other than linezolid, clindamycin, or TMP-SMX. Health 
care resource utilization and costs were determined for each pathway. Results: A 
total of 1418 patients met all of inclusion/exclusion criteria. The majority of patients 
either continued Vancomycin IV (46.5%) or switched to oral linezolid (41.4%) at dis-
charge. Only about 12% of patients were switched to Daptomycin or other non-MRSA 
active oral antibiotics. The average ABSSSI-related total health care cost was $16,571 
for the entire ABSSSI treatment. Total costs were comprised of $12,519 (75.5%) for 
inpatient cost, $201 (1.2%) for emergency department (ED) visits, $879 (5.3%) for 
outpatient treatment/office visits, and $1,015(6.1%) for pharmacy claims cost. The 
costs overall and in various locations of care varied by pathway. ConClusions: 
Inpatient treatment remains the largest component of total ABSSSI treatment cost. 
Utilization of linezolid and daptomycin increased the pharmacy or OPAT costs.
PIN59
ComParIsoN of the health Care Costs aNd UtIlIzatIoNs BetWeeN 
PatIeNts dIagNosed WIth the hePatItIs B vIrUs versUs those WIthoUt
Xie L.1, Wang L.2, Kariburyo M.F.1, Li L.2, Wang Y.1, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
objeCtives: To examine the economic burden and health care utilizations 
of patients diagnosed with the hepatitis B virus (HBV) in the U.S. veteran 
population. Methods: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets from October 1, 2008 to 
September 30, 2012. Patients diagnosed with HBV were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM 070.22, 070.23, 
070.32, 070.33, V02,61) diagnosis codes. The first diagnosis date was defined as the 
index date. A group of patients of the same age, region, gender and index year but 
without HBV infection were identified and matched by baseline Charlson Comorbidity 
Index (CCI) as the comparison group. A 1-year continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, including 
health care costs and utilizations, were compared between the HBV and compara-
tor groups using 1:1 propensity score matching. Results: A total of 9,718 patients 
were identified for the HBV and comparison cohorts. After applying a 1:1 matching, 
a total of 3,093 patients were matched from each cohort, and the baseline character-
istics were proportionate. Patients diagnosed with HBV infection were more likely to 
report higher health care utilizations, including inpatient (28.74% vs. 3.3%, p< 0.01), 
emergency room (25.67% vs. 8.3%, p< 0.01), physician office (98.60% vs. 62.75%) and 
pharmacy visits (88.23% vs. 63.65%, p< 0.01). The risk-adjusted health care costs were 
also higher for patients infected with HBV due to increased inpatient ($10,481 vs. $804, 
p< 0.01), emergency room ($382 vs. $80, p< 0.01), physician office ($4,635 vs. $1,678, 
p< 0.01), and pharmacy visits ($1,166 vs. $398, p< 0.01) resulting in higher total costs 
($16,909 vs. $3,045, p< 0.01) relative to the comparator cohort. ConClusions: During 
a period of 12 months, VHA patients diagnosed with HBV reported higher health care 
utilization and costs than their matched controls.
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objeCtives: Since Greece came under the regime of IMF and signed the memo-
randum, several curtailments had to be made to various areas of the public sec-
tor. Drug treatment seems to be quite expensive. As part of the strict economic 
rules, Greek hospitals were obliged to reduce their health care costs. The phar-
macy of each hospital incurred considerable weight of this attempt. One of its 
implemented actions was the drugs’ price negotiation with the pharmaceuti-
cal companies. Methods: In order to measure the effectiveness of this action, 
we performed a comparative study of the antibiotics used in 3 hospitals, PAGNI, 
Evaggelismos and Tzaneio. PAGNI and Evaggelismos are among the 5 biggest hos-
pitals of Greece (pharmaceutical budget around 40M€ ) while Tzaneio is a small 
